Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT01806064. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a lead-in Phase 1B Dose Escalation Portion) in Patients With Advanced or Metastatic Renal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 1b: To evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose axitinib in patients with advanced renal cell carcinoma. Phase 2: To estimate the PFS of patients with advanced or metastatic RCC by RECIST 1.1 criteria in patients treated with axitinib and TRC105 compared to those treated with axitinib alone, following failure of one prior VEGF TKI
Study identification
- NCT ID
- NCT01806064
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 173 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 8, 2013 (Actual)
- Primary completion
- Dec 21, 2018 (Actual)
- Completion
- Jun 12, 2019 (Actual)
- Last update posted
- Oct 19, 2020
2013 – 2019
United States locations
- U.S. sites
- 28
- U.S. states
- 19
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Mayo Clinic Arizona | Scottsdale | Arizona | 85054 | — |
| City of Hope | Duarte | California | 91010 | — |
| St. Joseph Heritage Healthcare | Fullerton | California | 92805 | — |
| University of California, Irvine | Irvine | California | 92697 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| University of California, Davis | Sacramento | California | 95616 | — |
| University of Florida | Gainesville | Florida | 32611 | — |
| University of Miami | Miami | Florida | 33124 | — |
| Moffitt Cancer Center | Tampa | Florida | 100271 | — |
| Illinois CancerCare | Peoria | Illinois | 61615 | — |
| Indiana Univeristy | Indianapolis | Indiana | 47405 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| University of Kentucky | Lexington | Kentucky | 40526 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 220071 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Washington University in St. Louis | St Louis | Missouri | 63110 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68124 | — |
| Atlantic Health System | Morristown | New Jersey | 07960 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Vanderbilt University | Nashville | Tennessee | 37232 | — |
| Joe Arrington Cancer Research & Treatment Center | Lubbock | Texas | 79410 | — |
| University of Utah | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01806064, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2020 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01806064 live on ClinicalTrials.gov.